4:46 PM
 | 
Nov 14, 2012
 |  BC Extra  |  Company News

Forest, Adamas partner for fixed-dose Alzheimer's combo

Forest Laboratories Inc. (NYSE:FRX) and Adamas Pharmaceuticals Inc. (Emeryville, Calif.) partnered to develop and commercialize Adamas' Arimenda ( ADS-8704) in the U.S. to treat moderate to severe Alzheimer's disease. The product is a once-daily, fixed-dose combination of extended release memantine...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >